CABA
Cabaletta Bio, Inc.
$3.88
-3.00%
2026-05-08
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Key Fundamentals
Forward P/E
-2.76
EPS (TTM)
$-2.10
ROE
-127.0%
Profit Margin
0.0%
Debt/Equity
24.18
Price/Book
3.48
Beta
3.17
Market Cap
$632.6M
Avg Volume (10D)
6.3M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$4.23
60D Low
$2.45
Avg Volume
3.0M
Latest Close
$3.88
Get breakout alerts for CABA
Sign up for Breakout Scanner to receive daily notifications when CABA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Cabaletta Bio, Inc. (CABA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CABA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CABA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.